Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model

Osteoporosis is characterized by a decrease in bone microarchitecture with an increased risk of fracture. Long-term use of primary treatments, such as bisphosphonates and selective estrogen receptor modulators, results in various side effects. Therefore, it is necessary to develop alternative therap...

Full description

Bibliographic Details
Main Authors: Minsun Kim, MinBeom Kim, Jae-Hyun Kim, SooYeon Hong, Dong Hee Kim, Sangwoo Kim, Eun-Young Kim, Hyuk-Sang Jung, Youngjoo Sohn
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2021/5521562
id doaj-2d07125cd230436482fdca3da78396ed
record_format Article
spelling doaj-2d07125cd230436482fdca3da78396ed2021-04-12T01:24:21ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-42882021-01-01202110.1155/2021/5521562Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat ModelMinsun Kim0MinBeom Kim1Jae-Hyun Kim2SooYeon Hong3Dong Hee Kim4Sangwoo Kim5Eun-Young Kim6Hyuk-Sang Jung7Youngjoo Sohn8Department of AnatomyDepartment of AnatomyDepartment of AnatomyDepartment of AnatomyDepartment of AnatomyDepartment of AnatomyDepartment of AnatomyDepartment of AnatomyDepartment of AnatomyOsteoporosis is characterized by a decrease in bone microarchitecture with an increased risk of fracture. Long-term use of primary treatments, such as bisphosphonates and selective estrogen receptor modulators, results in various side effects. Therefore, it is necessary to develop alternative therapeutics derived from natural products. Crataegus pinnatifida Bunge (CPB) is a dried fruit used to treat diet-induced indigestion, loss of appetite, and diarrhea. However, research into the effects of CPB on osteoclast differentiation and osteoporosis is still limited. In vitro experiments were conducted to examine the effects of CPB on RANKL-induced osteoclast differentiation in RAW 264.7 cells. Moreover, we investigated the effects of CPB on bone loss in the femoral head in an ovariectomized rat model using microcomputed tomography. In vitro, tartrate-resistant acid phosphatase (TRAP) staining results showed the number of TRAP-positive cells, and TRAP activity significantly decreased following CPB treatment. CPB also significantly decreased pit formation. Furthermore, CPB inhibited osteoclast differentiation by suppressing NFATc1, and c-Fos expression. Moreover, CPB treatment inhibited osteoclast-related genes, such as Nfatc1, Ca2, Acp5, mmp9, CtsK, Oscar, and Atp6v0d2. In vivo, bone mineral density and structure model index were improved by administration of CPB. In conclusion, CPB prevented osteoclast differentiation in vitro and prevented bone loss in vivo. Therefore, CPB could be a potential alternative medicine for bone diseases, such as osteoporosis.http://dx.doi.org/10.1155/2021/5521562
collection DOAJ
language English
format Article
sources DOAJ
author Minsun Kim
MinBeom Kim
Jae-Hyun Kim
SooYeon Hong
Dong Hee Kim
Sangwoo Kim
Eun-Young Kim
Hyuk-Sang Jung
Youngjoo Sohn
spellingShingle Minsun Kim
MinBeom Kim
Jae-Hyun Kim
SooYeon Hong
Dong Hee Kim
Sangwoo Kim
Eun-Young Kim
Hyuk-Sang Jung
Youngjoo Sohn
Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model
Evidence-Based Complementary and Alternative Medicine
author_facet Minsun Kim
MinBeom Kim
Jae-Hyun Kim
SooYeon Hong
Dong Hee Kim
Sangwoo Kim
Eun-Young Kim
Hyuk-Sang Jung
Youngjoo Sohn
author_sort Minsun Kim
title Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model
title_short Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model
title_full Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model
title_fullStr Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model
title_full_unstemmed Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model
title_sort crataegus pinnatifida bunge inhibits rankl-induced osteoclast differentiation in raw 264.7 cells and prevents bone loss in an ovariectomized rat model
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-4288
publishDate 2021-01-01
description Osteoporosis is characterized by a decrease in bone microarchitecture with an increased risk of fracture. Long-term use of primary treatments, such as bisphosphonates and selective estrogen receptor modulators, results in various side effects. Therefore, it is necessary to develop alternative therapeutics derived from natural products. Crataegus pinnatifida Bunge (CPB) is a dried fruit used to treat diet-induced indigestion, loss of appetite, and diarrhea. However, research into the effects of CPB on osteoclast differentiation and osteoporosis is still limited. In vitro experiments were conducted to examine the effects of CPB on RANKL-induced osteoclast differentiation in RAW 264.7 cells. Moreover, we investigated the effects of CPB on bone loss in the femoral head in an ovariectomized rat model using microcomputed tomography. In vitro, tartrate-resistant acid phosphatase (TRAP) staining results showed the number of TRAP-positive cells, and TRAP activity significantly decreased following CPB treatment. CPB also significantly decreased pit formation. Furthermore, CPB inhibited osteoclast differentiation by suppressing NFATc1, and c-Fos expression. Moreover, CPB treatment inhibited osteoclast-related genes, such as Nfatc1, Ca2, Acp5, mmp9, CtsK, Oscar, and Atp6v0d2. In vivo, bone mineral density and structure model index were improved by administration of CPB. In conclusion, CPB prevented osteoclast differentiation in vitro and prevented bone loss in vivo. Therefore, CPB could be a potential alternative medicine for bone diseases, such as osteoporosis.
url http://dx.doi.org/10.1155/2021/5521562
work_keys_str_mv AT minsunkim crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT minbeomkim crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT jaehyunkim crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT sooyeonhong crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT dongheekim crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT sangwookim crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT eunyoungkim crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT hyuksangjung crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
AT youngjoosohn crataeguspinnatifidabungeinhibitsranklinducedosteoclastdifferentiationinraw2647cellsandpreventsbonelossinanovariectomizedratmodel
_version_ 1714682952906964992